Paliperidon Tad (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors, which are involved in the regulation of mood, perception, and thought processes. This antagonism reduces excessive dopaminergic activity that contributes to psychotic symptoms, while also modulating serotonergic pathways to improve overall psychiatric stability.

The dosage of Paliperidon Tad is individualized and set by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Physicians determine the appropriate strength and frequency, and patients should follow the prescribed regimen without making adjustments on their own.

Paliperidon Tad is generally not recommended during pregnancy unless the potential benefits outweigh the risks, as safety data are limited. It is also contraindicated while breastfeeding because the drug can be excreted in breast milk and may affect the infant. Consultation with a healthcare provider is essential.

To request Paliperidon Tad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Paliperidon Tad, as the active metabolite of risperidone, offers a similar efficacy profile to other atypical antipsychotics but may have a lower risk of certain metabolic side effects. Compared with older typical antipsychotics, it generally produces fewer extrapyramidal symptoms, though individual response and tolerability can vary.

Paliperidon Tad should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Paliperidon Tad is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption and therapeutic effect.

The most serious risks include tardive dyskinesia, neuroleptic malignant syndrome, severe hyperglycemia, orthostatic hypotension, and rare cases of agranulocytosis. Patients should be monitored regularly for early signs of these conditions, and any concerning symptoms should be reported to a healthcare professional promptly.

Paliperidon Tad is contraindicated in individuals with known hypersensitivity to paliperidone or any of its excipients, those with severe cardiovascular disorders that could be worsened by orthostatic hypotension, and patients with a history of neuroleptic malignant syndrome. It should also be used with caution in patients with uncontrolled diabetes or a history of seizures.